A robust Pilot and Feasibility Program will be an integral portion of the CONSORTIUM FOR HEREDITARY CAUSES OF NEPHROLITHIASIS AND KIDNEY FAILURE. The Rare Diseases Consortium will serve as an active incubator for novel ideas in nephrolithiasis research and patient care. Plans are to fund 2 projects at all times for the duration of this award. For this purpose, $100,000 has been budgeted each year, allowing approximately $50,000 per pilot project. One of the two pilot projects will be funded by money pledged from the Mayo Clinic Rochester research committee. The primary focus will be to support new protocols with high potential for advancing patient care amongst one or more of the patient cohorts in our consortium. Proposals from junior investigators will also be given special consideration for funding, although the program will also be open to established investigators as a means of encouraging them to develop new projects or avenues of research within this field. Projects with a high potential to produce preliminary data making them competitive for additional extramural funding will also be given higher priority. In years 1-2, we will fund a pilot project on developing technology for harvesting viable hepatocytes from livers removed at transplant. This project synchronizes well with aims of Project 1, and will open the door towards novel model systems and potential therapies for PH. The second pilot project will be funded by the Mayo Clinic Research Committee ($50,000 per year for 5 years pledged). These funds expand the overall resources and scope of the Rare Diseases Consortium. All proposals will be selected by the full Rare Diseases Consortium Pilot Project Committee, using a rigorous selection processed. Several possible candidates for future Pilot Projects have been identified. However, we have intentionally elected to not select this additional proposal at the time of submission. Instead, we will issue a new RFA and select the most promising proposal at the time of potential grant funding. In this manner, we will maintain flexibility and not lock the consortium into specific areas, but instead allow the possibility that novel areas can be supported that emerge over the next 12 to 18 months.
The Pilot Program will fund 2 projects at all times for a period of 1-2 years each. Maximal budget is $50,000/year. Goals are to fund promising nephrolithiasis investigators and provide preliminary data in support of promising new ideas.
|Tang, Xiaojing; Lieske, John C (2014) Acute and chronic kidney injury in nephrolithiasis. Curr Opin Nephrol Hypertens 23:385-90|
|Meeusen, Jeffrey W; Lieske, John C (2014) Looking for a better creatinine. Clin Chem 60:1036-9|
|Lieske, John C; Collazo-Clavell, Maria L; Sarr, Michael G et al. (2014) Gastric bypass surgery and measured and estimated GFR in women. Am J Kidney Dis 64:663-5|
|Ali, Farah N; Falkner, Bonita; Gidding, Samuel S et al. (2014) Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure. J Pediatr 165:738-43.e1|
|Fattah, Hasan; Hambaroush, Yasmin; Goldfarb, David S (2014) Cystine nephrolithiasis. Transl Androl Urol 3:228-233|
|Modersitzki, Frank; Pizzi, Laura; Grasso, Michael et al. (2014) Health-related quality of life (HRQoL) in cystine compared with non-cystine stone formers. Urolithiasis 42:53-60|
|Fervenza, Fernando C (2013) A patient with nephrotic-range proteinuria and focal global glomerulosclerosis. Clin J Am Soc Nephrol 8:1979-87|
|Lee, Hyo-Jung; Jeong, Soo-Jin; Lee, Hyo-Jeong et al. (2011) 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose reduces renal crystallization and oxidative stress in a hyperoxaluric rat model. Kidney Int 79:538-45|
|Goldfarb, David S (2011) Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria. Clin J Am Soc Nephrol 6:2093-7|
|Coe, Fredric L; Evan, Andrew; Worcester, Elaine (2011) Pathophysiology-based treatment of idiopathic calcium kidney stones. Clin J Am Soc Nephrol 6:2083-92|
Showing the most recent 10 out of 16 publications